Vivici Secures $14.4M EIC Accelerator Grant to Scale Precision‑fermented Dairy Proteins

Why It Matters

The funding accelerates large‑scale production of animal‑free dairy proteins, lowering costs and speeding market adoption. It signals strong European support for precision‑fermentation startups competing in the fast‑growing alternative‑protein sector.

Key Takeaways

• Vivici receives €12.5 M ($14.4 M) EIC grant and equity
• Integrated Enduro Genetics tech, boosting titers and yields by 30%
• Secured FDA GRAS for beta‑lactoglobulin and self‑GRAS for lactoferrin
• Partnered with Liberation Bioindustries for US production in Indiana
• Exploring 4‑million‑liter alt‑protein facility with Abu Dhabi Investment Office

Pulse Analysis

Vivici’s €12.5 million European Innovation Council award underscores the growing appetite for public‑private financing in the precision‑fermentation arena. The blended structure—combining grant money with equity—reduces capital risk for investors while giving the Dutch startup the runway to upgrade bioreactors, secure raw‑material contracts, and meet the volume thresholds needed for price parity with conventional dairy. Backed by dairy giants Fonterra and DSM‑Firmenich, Vivici can leverage deep industry expertise to navigate supply‑chain complexities and accelerate go‑to‑market strategies across Europe and beyond.

A technical breakthrough came when Vivici adopted Enduro Genetics’ cell‑productivity platform, which lifted protein titers and yields by roughly 30 percent. This improvement translates directly into lower fermentation costs and a smaller environmental footprint, two critical levers for scaling alternative proteins. Simultaneously, the company earned FDA GRAS clearance for beta‑lactoglobulin and self‑GRAS status for lactoferrin, milestones that de‑risk regulatory approval and open doors to mainstream food manufacturers seeking animal‑free whey and bioactive ingredients.

Strategic partnerships further amplify Vivici’s growth trajectory. A manufacturing deal with Liberation Bioindustries brings production capacity to Indiana, positioning the firm to serve the North American market swiftly. Meanwhile, collaboration with the Abu Dhabi Investment Office aims to develop a 4‑million‑liter facility in the UAE, signaling the Middle East’s commitment to alternative‑protein infrastructure. Together, these moves not only broaden Vivici’s geographic reach but also intensify competition among precision‑fermentation players, accelerating innovation and driving down costs for consumers worldwide.

Deal Summary

Dutch startup Vivici has been awarded €12.5 million ($14.4 million) from the European Innovation Council’s Accelerator Program, a blended grant and equity financing to scale its precision‑fermented dairy protein production. The funding will support industrial‑scale manufacturing and expansion into new markets. Vivici, founded by Fonterra and DSM‑Firmenich, aims to accelerate its alternative protein portfolio.